Medically Integrated Dispensing of Regorafenib for Metastatic Colorectal Cancer Patients

By adopting NCODA’s PQI resource tools, a peer-reviewed guidance for effective practices that improve knowledge exchange within a medically integrated dispensing (MID) pharmacy team and result in positive patient outcomes. This article will examine examples of common barriers within these treatment settings and provide suggestions to improve outcomes for metastatic colorectal cancer (mCRC) patients receiving Stivarga® (regorafenib) therapy.